SIGLEC1 and breast cancer: This indicates that critical immunoregulatory changes occur in interfollicular T-cell rich areas in human breast cancer LNM, indicating suppressed immune reactivity in interfollicular T-cells that previously have been shown to depend on CD169+ SCS macrophages [27].